Healthcare ResearchUAE
UAE Influenza Vaccines Report 2025-2026
4 Surprising Trends from Dubai's Top Hospitals
View Full Case Study
Client Research Portfolio
Real-World Research.
Measurable Results.
From GCC formulary strategy to European KOL engagement, our case studies showcase the depth and precision of BioNixus intelligence across the MENA & EMEA healthcare ecosystem.
127+
Projects Delivered
17+
Countries Covered
14+
Therapeutic Areas
25+
Clients Served
Evidence programs across GCC and Europe
Country
Healthcare ResearchEurope2026
CNS Case Study: 6 Surprising Takeaways Redefining the Future of Brain Health
A BioNixus CNS case study showing six shifts reshaping neurology: post-COVID demand expansion, metabolic-inflammation, gut-brain therapies, sober neuroplastogens, digital therapeutics, and blood-based diagnostics.
Read Case Study
Healthcare ResearchMENA2026
GCC Oncology Market Review
The Gulf Cooperation Council (GCC) region is facing a significant increase in cancer incidence, with growth rates projected to be approximately double the global average between 2020 and 2025. While Saudi Arabia (KSA) currently maintains the highest number of diagnosed cases, neighboring countries like Qatar, the UAE, and Kuwait are expected to see even faster growth
Read Case Study
Healthcare ResearchUAE2025
Biologics Market Analysis in UAE
As the complexity of care increases, the need for "Intelligence for Business Growth" has never been more urgent
Read Case Study
In Progress
Research In the Pipeline
Our team is actively conducting these research programmes. Results will be published shortly.
Q2 2026 Release
Market ResearchUAE · KSA
Biosimilar Uptake Dynamics — UAE & Saudi Arabia
Tracking physician adoption patterns for key biologics and biosimilars across GCC formulary systems.
Publishing Q2 2026
Q2 2026 Release
Qualitative ResearchEgypt · Kuwait
Oncology Patient Journey Mapping — Egypt & Kuwait
In-depth qualitative interviews with oncologists mapping referral pathways and unmet needs.
Publishing Q2 2026
Q3 2026 Release
Market AccessUK · Germany
HTA Submission Readiness — NICE & G‑BA Comparative Review
Evidence gap analysis and payer positioning for a specialty immunology product.
Publishing Q3 2026
Topics We Research
BioNixus has delivered intelligence across 12+ therapeutic areas and service types.
🧪Oncology Market Access
💊Rare Disease Insights
🫀Cardiovascular Research
🧠CNS Therapeutic Landscape
🏥Hospital Procurement
📋HTA Evidence Dossiers
🤝KOL Stakeholder Mapping
📊Physician Surveys
🌍Pan-MENA Rollouts
💉Immunology Landscapes
🔬Biosimilar Intelligence
📈Launch Readiness
Commission Your Own Research
Don't see your market or therapeutic area covered? We design bespoke research programmes for pharma and biotech leaders across MENA and EMEA.